Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases.
Currently, several drugs are accessible for the treatment of many chronic diseases (multiple sclerosis, amyotrophic lateral sclerosis, rheumatoid arthritis, etc.), but most of them have a large list of side effects. Here, we propose a new therapeutic approach called Endotherapia for the treatment of chronic diseases. This approach combines a biomedical evaluation of circulating immunoglobulins directed against specific self-antigens and self-antigens modified by free radicals. The therapy proposed here is a "tailor-made" combination of small molecules (e.g., fatty acids and vitamins) linked to a non-immunogenic chain of poly-L.Lysine (PLL). Each individual linkage or PLL derivative offers great advantages, such as an increase in the half-life of the active small molecules. Endotherapia also involves clinical aspects, allowing an exact diagnosis of the disease and the identification of specific circulating antibodies in the serum of patients in several clinical trials (e.g., multiple sclerosis). Endotherapia has been shown to be very safe. In summary, Endotherapia is the result of an immunopathological strategy addressing chronic incurable diseases with a multifactorial etiology. In light of the results obtained, it seems that Endotherapia is a promising therapy for chronic diseases, with no side effects, which is evidently mandatory in the management of long-term pathologies.
Institut pour le Développement de la Recherche en Pathologie Humaine et Thérapeutique, Talence, France. mg.idrpht@wanadoo.fr
Michel
M
Geffard
Laetitia
L
de Bisschop
Sébastien
S
Duleu
Nadine
N
Hassaine
Arturo
A
Mangas
Rafael
R
Coveñas
D000906:Antibodies / Q000097:blood; D001419:Bacteria / Q000472:pathogenicity; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D009103:Multiple Sclerosis / Q000628:therapy*
D000906:Antibodies